Logo
x

Search category

Subscribe Now

Alvotech

Alvotech Entered into an Exclusive License Agreement with Kashiv BioSciences to Develop and Commercialize AVT23, a Proposed Biosimilar to Xolair (omalizumab)

Alvotech Entered into an Exclusive License Agreement with Kashiv BioSciences to Develop and Commercialize AVT23, a Proposed Biosim...

  • October 4, 2023
Fuji Pharma Receives the MHLW Approval of AVT04 (biosimilar, ustekinumab) in Japan

Fuji Pharma Receives the MHLW Approval of AVT04 (biosimilar, ustekinumab) in Japan

  • September 25, 2023
Alvotech and Bioventure Receives Approval of AVT02 (biosimilar, adalimumab) from Egyptian Drug Authority in Egypt

Alvotech and Bioventure Receives Approval of AVT02 (biosimilar, adalimumab) from Egyptian Drug Authority in Egypt

  • August 29, 2023
Alvotech Highlighted 52wk. Study Results of AVT04 (biosimilar, ustekinumab) for Chronic Plaque Psoriasis

Alvotech Highlighted 52wk. Study Results of AVT04 (biosimilar, ustekinumab) for Chronic Plaque Psoriasis

  • August 18, 2023
Alvotech Receives Complete Response Letter on Second BLA for AVT02

Alvotech Receives Complete Response Letter on Second BLA for AVT02

  • June 28, 2023
Alvotech and Teva Settled with Johnson & Johnson for AVT04, a Proposed Biosimilar to Stelara (ustekinumab)

Alvotech and Teva Settled with Johnson & Johnson for AVT04, a Proposed Biosimilar to Stelara (ustekinumab)

  • June 12, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.